- Home
- VRE vs BCYC Comparison
VRE vs BCYC Comparison
Compare VRE & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRE
- BCYC
- Stock Information
- Founded
- VRE 1949
- BCYC 2009
- Country
- VRE United States
- BCYC United Kingdom
- Employees
- VRE N/A
- BCYC N/A
- Industry
- VRE Real Estate Investment Trusts
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- VRE Real Estate
- BCYC Health Care
- Exchange
- VRE Nasdaq
- BCYC Nasdaq
- Market Cap
- VRE 1.6B
- BCYC 1.7B
- IPO Year
- VRE 1994
- BCYC 2019
- Fundamental
- Price
- VRE $17.53
- BCYC $15.14
- Analyst Decision
- VRE Buy
- BCYC Buy
- Analyst Count
- VRE 4
- BCYC 9
- Target Price
- VRE $18.25
- BCYC $36.00
- AVG Volume (30 Days)
- VRE 410.7K
- BCYC 880.7K
- Earning Date
- VRE 10-30-2024
- BCYC 10-31-2024
- Dividend Yield
- VRE 1.59%
- BCYC N/A
- EPS Growth
- VRE N/A
- BCYC N/A
- EPS
- VRE N/A
- BCYC N/A
- Revenue
- VRE $293,369,000.00
- BCYC $36,898,000.00
- Revenue This Year
- VRE N/A
- BCYC $40.52
- Revenue Next Year
- VRE $4.50
- BCYC N/A
- P/E Ratio
- VRE N/A
- BCYC N/A
- Revenue Growth
- VRE 11.63
- BCYC 48.60
- 52 Week Low
- VRE $13.84
- BCYC $12.17
- 52 Week High
- VRE $18.85
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- VRE 43.44
- BCYC 28.66
- Support Level
- VRE $17.38
- BCYC $12.17
- Resistance Level
- VRE $17.73
- BCYC $21.50
- Average True Range (ATR)
- VRE 0.28
- BCYC 1.33
- MACD
- VRE -0.07
- BCYC -0.46
- Stochastic Oscillator
- VRE 18.97
- BCYC 31.83
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.